Bioject to Be Transferred to the over-the-Counter Bulletin Board

PORTLAND, Ore.--(Business Wire)--
Bioject Medical Technologies Inc. (NASDAQ:BJCT), a leading
developer of needle-free injection therapy systems, today announced
that it has received notification from The NASDAQ Stock Market LLC
that the NASDAQ Listing Qualifications Panel has determined to delist
the Company's securities from The NASDAQ Capital Market. The Panel's
decision was based on the fact that the Company has not regained
compliance with NASDAQ's $1.00 per share bid price requirement.

Accordingly, trading in the Company's common stock will be
transferred to the Over-the-Counter Bulletin Board (the "OTCBB"), an
electronic quotation service maintained by the Financial Industry
Regulatory Authority, effective with the open of the market on July
23, 2008. The symbol will remain BJCT.

"While today's financial market conditions are challenging, the
Company remains highly committed to working on our core fundamentals
and pursuing our new business strategy," said Ralph Makar, President
and CEO of Bioject. "We look forward to sharing more information
during our next earnings call."

About Bioject

Bioject Medical Technologies Inc., based in Portland, Oregon, is
an innovative developer and manufacturer of needle-free injection
therapy systems (NFITS). NFITS provide an empowering technology and
works by forcing medication at high speed through a tiny orifice held
against the skin. This creates a fine stream of high-pressure fluid
penetrating the skin and depositing medication in the tissue beneath.
The Company is focused on developing mutually beneficial agreements
with leading pharmaceutical, biotechnology, and veterinary companies.
For more information about Bioject, visit www.bioject.com.

About the OTCBB

The OTCBB is a regulated quotation service that displays real-time
quotes, last-sale prices, and volume information in OTC equity
securities. An OTC equity security generally is any equity that is not
listed or traded on a national securities exchange. OTCBB securities
include national, regional, and foreign equity issues, warrants,
units, ADRs, and Direct Participation Programs. More information is
available at http://www.otcbb.com.

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
regarding quotation on the OTC Bulletin Board. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different
from any future results expressed or implied by such forward-looking
statements. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. The
Company assumes no obligation to update forward-looking statements if
conditions or management's estimates or opinions should change.

For more information about Bioject, visit www.bioject.com.

Bioject Medical Technologies Inc.
Ralph Makar, President and CEO
503-692-8001, ext. 4137
or
Chris Farrell, Vice President of Finance
503-692-8001, ext. 4132

Copyright Business Wire 2008